抗体偶联药物的不良反应与药学监护

Adverse Reactions and Pharmaceutical Care of Antibody-Drug Conjugates

关键词:  抗体偶联药物  肿瘤  药学监护  不良反应  安全性管理  

Key words:  antibody-drug conjugates  tumor  pharmaceutical care  adverse reactions  safety management  

摘要:

抗体偶联药物是由单克隆抗体通过连接子与细胞毒药物偶联而成的新型肿瘤治疗药物。相比于传统的治疗方法，如手术、放疗、化疗等，抗体偶联药物在保留对肿瘤细胞高效杀伤作用的同时，显著降低对正常组织的损害。自2000年首个抗体偶联药物药物上市以来，抗体偶联药物被广泛应用于多种血液瘤与实体瘤的治疗。然而在抗体偶联药物的临床应用中，累及血液系统、周围神经、肺、肝等脏器的药物不良反应不容忽视。为此我们从药学角度出发，对抗体偶联药物的结构组成、作用机制、不良反应及其药学监护等方面进行全面综述，旨为抗体偶联药物的临床合理应用提供参考和建议。

Abstract:

Antibody-drug conjugates (ADCs) are novel tumor therapeutics composed of a linker, cytotoxic drug and monoclonal antibody. Compared with traditional treatments such as surgery, radiotherapy, and chemotherapy, ADCs significantly reduce toxicity to normal tissues, while retaining the potent tumor-killing effect, enabling precise and ef?cient elimination of tumors. Since the first ADCs was approved in 2000, ADCs have been widely used in various cancers, including hematologic neoplasms and solid tumors. However, the adverse reaction, involving hematological, peripheral nerves, cardiac and other systems, cannot be ignored. Here, we comprehensively review the structural composition, mechanism of action, adverse reactions and pharmaceutical care of ADCs, aiming to provide suggestions for the rational clinical application of ADCs.